%0 Case Reports
%T Aortitis after switching short-acting granulocyte colony-stimulating factors in a lymphoma patient with HLA-B52.
%A Tane M
%A Kosako H
%A Hosoi H
%A Furuya Y
%A Hori Y
%A Yamashita Y
%A Murata S
%A Mushino T
%A Sonoki T
%J Int J Hematol
%V 119
%N 5
%D 2024 May 23
%M 38521841
%F 2.319
%R 10.1007/s12185-024-03744-w
%X Aortitis is a rare adverse event of granulocyte colony-stimulating factor (G-CSF) treatment. Several previous studies have described recurrent aortitis caused by re-administration of the same G-CSF. However, no previous studies have examined the safety of switching between short-acting G-CSFs in patients who develop aortitis. We report the case of a 55-year-old man with refractory diffuse large B-cell lymphoma, who developed G-CSF-associated aortitis. The aortitis was triggered by filgrastim and recurred after treatment with lenograstim. The patient possessed human leukocyte antigen B52, which has been implicated in Takayasu arteritis. In addition, a drug-induced lymphocyte stimulation test for lenograstim performed upon detection of recurrent G-CSF-associated aortitis produced a positive result. Our case suggests that switching from one short-acting G-CSF to another does not prevent recurrence of G-CSF-associated aortitis. Although the etiology of G-CSF-associated aortitis has not been fully elucidated, our case also suggests that some patients may be genetically predisposed to aortitis.